Collectively, the above data indicate that the inclusion of additional antigens (TB10.4 and RpfB) into our trivalent ChAd-vectored vaccine design further improves its protective capacity against pulmonary tuberculosis. This evidence concerns the gene TMSB10 and pulmonary tuberculosis.